Garon EB, Cho BC, Luft A, Alatorre-Alexander J, et al. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON). Lung Cancer 2023;186:107422.
PMID: 37992595